Press Room

Webinar - PRIME: A Knowledge-based Assessment Tool to Classify Pharmaceutical Processes

Start
Monday, May 11, 2020 - 16:00
End
Monday, May 11, 2020 - 17:00
Location: online
Webinar Drug Substance Pharmaceutical Processes | Hovione

 

Watch On-Demand Webinar

 

Speakers

Rui Loureiro - Director, R&D Process Chemistry Development
Filipe Ataíde - Senior Scientist, R&D Process Chemistry Development

 

The manufacturing of API is a long and complex process. The comparison between the different processes is not easy since the chemical structures vary and therefore the compounds physical properties also change.

 

In this webinar we will be presenting the tool we developed to be able to take advantage of 60 years of experience in developing API process. The use of this tool allows us to develop our clients' projects using a Development by Design approach and to better manage the expectations of different outputs at different lifecycle stages of the processes. This follows a structured approach which allows for a faster process development.

 

What can you learn from this webinar?

  • How we score processes
  • How the knowledge can be used to develop an API manufacturing by design
  • How we can speed-up the process development

Join this webinar where our speakers will share their views on this new tool that is able to accelerate the development process.

 

Watch On-Demand Webinar

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026